Hypoxia-inducible factor 2α (HIF2α), a transcription factor pivotal to cellular adaptation under low oxygen conditions, has long stood as a formidable therapeutic challenge. Its designation as “undruggable” stemmed from the difficulty in targeting transcription factors with small molecules, due to their structurally complex and often fluid interaction surfaces. However, an extraordinary breakthrough emerged with the identification of an allosteric pocket within HIF2α’s PAS-B domain. This discovery paved the way for the rational design of selective small-molecule antagonists, culminating in a new class of drugs that could directly inhibit HIF2α activity. At the forefront of this innovation is belzutifan, a pioneering HIF2α inhibitor that has redefined therapeutic strategies for cancers driven by hypoxia and VHL pathway aberrations.
The clinical development of belzutifan marks a historic moment in oncology, particularly for patients suffering from von Hippel–Lindau (VHL) disease-associated tumors and clear-cell renal cell carcinoma (ccRCC), conditions notoriously resistant to conventional treatments. Belzutifan’s efficacy against highly vascularized tumors characteristic of VHL disease provided compelling proof-of-concept, confirming that HIF2α is not only druggable but also a viable, impactful target in human malignancies. This success catalyzed expanded clinical evaluations in sporadic ccRCC and rare neuroendocrine tumors such as pheochromocytomas and paragangliomas, further underscoring the broad therapeutic relevance of HIF2α inhibition.
Unpacking the biology underpinning VHL–HIF signaling is essential to appreciate the transformative potential of HIF2α inhibitors. Under normoxic conditions, the VHL protein orchestrates the degradation of HIFα subunits, including HIF2α, by tagging them for proteasomal breakdown. Loss or mutation of VHL leads to the stabilization of HIFα, which in turn activates transcriptional programs promoting angiogenesis, metabolic reprogramming, and cell survival under hypoxia. This pathway’s dysregulation is central to the pathogenesis of ccRCC and several other tumor types, making it an appealing node for therapeutic intervention. The selective blockade of HIF2α directly disrupts these oncogenic processes, effectively starving tumors of their adaptive advantage in hypoxic microenvironments.
The structural elucidation of HIF2α’s PAS-B domain revolutionized drug design, as it revealed a druggable cavity that was previously undetected. This pocket, distinct from the orthosteric DNA-binding interfaces, permits allosteric modulation, which translates into the specific inhibition of HIF2α’s protein-protein interactions necessary for transcriptional activity. This mechanistic insight has been exploited to develop small molecules capable of stabilizing the PAS-B domain in an inactive conformation, preventing the assembly of HIF2α transcriptional complexes. These inhibitors demonstrate exquisite selectivity, minimizing off-target effects that historically plagued transcription factor targeting efforts.
Belzutifan’s clinical trajectory highlights the dynamic interplay between structural biology, medicinal chemistry, and oncology. Following promising preclinical data, phase 1 and phase 2 trials revealed robust anti-tumor activity coupled with a manageable safety profile. The drug has been granted multiple regulatory approvals, notably for VHL-disease-associated ccRCC and other tumors, signifying a paradigm shift in managing these previously intractable cancers. Belzutifan’s success also spurred the development of next-generation HIF2α inhibitors, aiming to optimize pharmacokinetics, enhance potency, and overcome emerging resistance mechanisms.
Beyond small molecules, emerging therapeutic modalities are being investigated to expand the arsenal against HIF2α-driven cancers. RNA interference (RNAi) technologies provide a complementary approach by selectively silencing HIF2α gene expression, potentially enhancing the depth and durability of pathway suppression. Additionally, indirect modulators targeting upstream or downstream components of the hypoxia response pathway may synergize with direct inhibitors, broadening treatment landscapes and overcoming tumor heterogeneity.
Combination therapy strategies represent a frontier with immense promise. By pairing HIF2α inhibitors with immune checkpoint inhibitors, anti-angiogenic agents, or targeted therapies against metabolic vulnerabilities, clinicians aim to amplify therapeutic efficacy and forestall resistance. However, critical challenges remain. Identifying predictive biomarkers to select patients most likely to benefit from HIF2α inhibition is an urgent priority to tailor precision oncology approaches. Furthermore, unraveling the biological mechanisms underpinning primary and acquired resistance will inform next-generation drug development and rational combination regimens.
The management of on-target toxicities such as anemia and hypoxia presents another clinical consideration. Since HIF2α modulates erythropoiesis and oxygen sensing, its inhibition can disrupt normal physiological processes, necessitating vigilant monitoring and robust supportive care protocols. Optimal dosing schedules and mitigation strategies are under active exploration to maximize patient tolerability and maintain sustained anti-tumor activity.
The potential indications for HIF2α inhibitors extend well beyond renal malignancies. Multiple hypoxia-adapted cancers—including neuroendocrine tumors, glioblastomas, and certain sarcomas—demonstrate reliance on HIF2α-mediated transcriptional programs, suggesting wider applicability. Expanding clinical trials into these domains may unlock previously untapped therapeutic avenues, reinforcing HIF2α inhibition as a cornerstone of oncology drug development.
Looking forward, translational research must prioritize delineating the complex tumor microenvironment interactions shaped by HIF2α signaling. Integrative genomic, proteomic, and metabolomic studies will yield comprehensive insights into tumor dependencies and resistance pathways. These endeavors will also aid in the discovery of synergistic drug combinations, rational dosing strategies, and biomarkers predictive of response and toxicity.
In summary, the advent of HIF2α inhibitors like belzutifan epitomizes a triumph in targeting a historically elusive transcription factor, opening new frontiers in cancer therapy. The fusion of structural biology breakthroughs with clinical innovation exemplifies how foundational science can rapidly translate into impactful therapeutic advances. As the clinical landscape evolves, continued multidisciplinary efforts will be essential to harness the full potential of HIF2α inhibition, transforming outcomes for patients with a spectrum of hypoxia-driven malignancies.
Subject of Research:
The development and clinical application of hypoxia-inducible factor 2α (HIF2α) inhibitors in oncology.
Article Title:
The clinical landscape of HIF2α inhibitors in oncology.
Article References:
Saad, E., Machaalani, M., McDermott, D.F. et al. The clinical landscape of HIF2α inhibitors in oncology. Nat Rev Clin Oncol (2026). https://doi.org/10.1038/s41571-026-01145-y
Image Credits: AI Generated
Tags: allosteric inhibition of transcription factorsbelzutifan clinical developmentclear-cell renal cell carcinoma therapiesHIF2α inhibitors in cancer therapyhypoxia-inducible factor targeting drugsneuroendocrine tumor treatment advancesnovel cancer drug design strategiesovercoming resistance in cancer therapysmall-molecule antagonists for HIF2αtargeting hypoxia in tumorsVHL pathway cancer mechanismsVon Hippel-Lindau disease treatment
